CVE:IBT

IBEX Technologies Competitors

C$0.38
-0.01 (-2.56 %)
(As of 04/19/2021 03:41 PM ET)
Add
Compare
Today's Range
C$0.38
Now: C$0.38
C$0.39
50-Day Range
C$0.28
MA: C$0.33
C$0.40
52-Week Range
C$0.11
Now: C$0.38
C$0.40
Volume39,550 shs
Average Volume26,318 shs
Market CapitalizationC$9.41 million
P/E Ratio7.04
Dividend YieldN/A
BetaN/A

Competitors

IBEX Technologies (CVE:IBT) Vs. QPT, CZO, CTX, KNE, GSD, and PAS

Should you be buying IBT stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to IBEX Technologies, including Quest PharmaTech (QPT), Ceapro (CZO), Crescita Therapeutics (CTX), Kane Biotech (KNE), Devonian Health Group (GSD), and Pascal Biosciences (PAS).

IBEX Technologies (CVE:IBT) and Quest PharmaTech (CVE:QPT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Profitability

This table compares IBEX Technologies and Quest PharmaTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IBEX TechnologiesN/AN/AN/A
Quest PharmaTechN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for IBEX Technologies and Quest PharmaTech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IBEX Technologies0000N/A
Quest PharmaTech0000N/A

Valuation and Earnings

This table compares IBEX Technologies and Quest PharmaTech's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IBEX TechnologiesC$5.60 million1.68C$1.34 millionC$0.057.04
Quest PharmaTechC$38,871.00474.71C$109.88 millionC$0.660.17

Quest PharmaTech has lower revenue, but higher earnings than IBEX Technologies. Quest PharmaTech is trading at a lower price-to-earnings ratio than IBEX Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Quest PharmaTech beats IBEX Technologies on 3 of the 5 factors compared between the two stocks.

IBEX Technologies (CVE:IBT) and Ceapro (CVE:CZO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Profitability

This table compares IBEX Technologies and Ceapro's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IBEX TechnologiesN/AN/AN/A
CeaproN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for IBEX Technologies and Ceapro, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IBEX Technologies0000N/A
Ceapro0000N/A

Valuation and Earnings

This table compares IBEX Technologies and Ceapro's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IBEX TechnologiesC$5.60 million1.68C$1.34 millionC$0.057.04
CeaproC$16.14 million3.56C$2.56 millionC$0.0322.42

Ceapro has higher revenue and earnings than IBEX Technologies. IBEX Technologies is trading at a lower price-to-earnings ratio than Ceapro, indicating that it is currently the more affordable of the two stocks.

Summary

Ceapro beats IBEX Technologies on 4 of the 5 factors compared between the two stocks.

IBEX Technologies (CVE:IBT) and Crescita Therapeutics (TSE:CTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Profitability

This table compares IBEX Technologies and Crescita Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IBEX TechnologiesN/AN/AN/A
Crescita TherapeuticsN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for IBEX Technologies and Crescita Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IBEX Technologies0000N/A
Crescita Therapeutics0000N/A

Valuation and Earnings

This table compares IBEX Technologies and Crescita Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IBEX TechnologiesC$5.60 million1.68C$1.34 millionC$0.057.04
Crescita TherapeuticsC$15.64 million1.06C$41,296.00C$0.00400.00

IBEX Technologies has higher earnings, but lower revenue than Crescita Therapeutics. IBEX Technologies is trading at a lower price-to-earnings ratio than Crescita Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

IBEX Technologies beats Crescita Therapeutics on 3 of the 5 factors compared between the two stocks.

IBEX Technologies (CVE:IBT) and Kane Biotech (CVE:KNE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Profitability

This table compares IBEX Technologies and Kane Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IBEX TechnologiesN/AN/AN/A
Kane BiotechN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for IBEX Technologies and Kane Biotech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IBEX Technologies0000N/A
Kane Biotech0000N/A

Valuation and Earnings

This table compares IBEX Technologies and Kane Biotech's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IBEX TechnologiesC$5.60 million1.68C$1.34 millionC$0.057.04
Kane BiotechC$1.34 million15.38C$-3,801,490.00C($0.04)-5.43

IBEX Technologies has higher revenue and earnings than Kane Biotech. Kane Biotech is trading at a lower price-to-earnings ratio than IBEX Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

IBEX Technologies beats Kane Biotech on 4 of the 5 factors compared between the two stocks.

IBEX Technologies (CVE:IBT) and Devonian Health Group (CVE:GSD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Valuation and Earnings

This table compares IBEX Technologies and Devonian Health Group's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IBEX TechnologiesC$5.60 million1.68C$1.34 millionC$0.057.04
Devonian Health GroupC$1.59 million15.20C$-4,457,184.00C($0.05)-5.42

IBEX Technologies has higher revenue and earnings than Devonian Health Group. Devonian Health Group is trading at a lower price-to-earnings ratio than IBEX Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for IBEX Technologies and Devonian Health Group, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IBEX Technologies0000N/A
Devonian Health Group0000N/A

Profitability

This table compares IBEX Technologies and Devonian Health Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IBEX TechnologiesN/AN/AN/A
Devonian Health GroupN/AN/AN/A

Summary

IBEX Technologies beats Devonian Health Group on 4 of the 5 factors compared between the two stocks.

Pascal Biosciences (CVE:PAS) and IBEX Technologies (CVE:IBT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk.

Earnings and Valuation

This table compares Pascal Biosciences and IBEX Technologies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pascal BiosciencesN/AN/AN/AC($0.02)-3.64
IBEX TechnologiesC$5.60 million1.68C$1.34 millionC$0.057.04

IBEX Technologies has higher revenue and earnings than Pascal Biosciences. Pascal Biosciences is trading at a lower price-to-earnings ratio than IBEX Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Pascal Biosciences and IBEX Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pascal Biosciences0000N/A
IBEX Technologies0000N/A

Profitability

This table compares Pascal Biosciences and IBEX Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pascal BiosciencesN/AN/AN/A
IBEX TechnologiesN/AN/AN/A

Summary

IBEX Technologies beats Pascal Biosciences on 3 of the 3 factors compared between the two stocks.


IBEX Technologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
QPT
Quest PharmaTech
0.8$0.11-13.6%C$21.76 millionC$38,871.000.17Gap Down
CZO
Ceapro
0.7$0.74-1.4%C$21.65 millionC$16.14 million22.42
CTX
Crescita Therapeutics
0.6$0.80-6.3%C$16.52 millionC$15.64 million400.00
KNE
Kane Biotech
0.4$0.19-0.0%C$14.12 millionC$1.34 million-5.43
GSD
Devonian Health Group
0.5$0.26-3.8%C$13.96 millionC$1.59 million-5.42High Trading Volume
PAS
Pascal Biosciences
0.6$0.08-6.3%C$12.70 millionN/A-3.64
NSP
Naturally Splendid Enterprises
0.6$0.06-0.0%C$11.06 millionC$2.03 million-1.40
MPH
Medicure
0.7$1.63-1.2%C$10.80 millionC$12.71 million-1.05Gap Up
BTI
Bioasis Technologies
0.7$0.34-1.5%C$10.16 millionC$4.12 million30.45Gap Down
HEM
Hemostemix
0.6$0.33-6.2%C$9.07 millionN/A-1.93Gap Down
ICO
iCo Therapeutics
0.5$0.11-0.0%C$7.69 millionN/A-8.75
IOT
Innovotech
0.8$0.17-5.9%C$6.52 millionC$1.04 million85.00Gap Down
BCT
BriaCell Therapeutics
0.5$3.61-5.8%C$4.48 millionN/A-1.17
RVV
Revive Therapeutics
0.5$0.08-12.5%C$3.62 millionN/A-3.64High Trading Volume
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04-71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03-16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01-0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.3$46.81-1.6%C$0.00C$267.59 million51.44
LTY
Liberty Biopharma
0.6$2.00-100.0%C$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
SCYB
Scythian Biosciences
0.5$3.49-6.3%C$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32-5.3%C$0.00N/A0.00News Coverage
Gap Down
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.